

Resource Summary Report

Generated by [PRECISE-TBI](#) on Aug 9, 2026

MABTECH

RRID:SCR_013398

Type: Tool

Proper Citation

MABTECH (RRID:SCR_013398)

Resource Information

URL: <https://www.mabtech.com/>

Proper Citation: MABTECH (RRID:SCR_013398)

Description: An Antibody supplier

Synonyms: Mabtech AB

Resource Type: commercial organization

Resource Name: MABTECH

Resource ID: SCR_013398

Alternate IDs: nlx_152403, grid.452552.1

Alternate URLs: <https://ror.org/057s3rs39>

Record Creation Time: 20220129T080315+0000

Record Last Update: 20260808T185955+0000

Ratings and Alerts

No rating or validation information has been found for MABTECH.

No alerts have been found for MABTECH.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 3389 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Nassuuna J, et al. (2025) Helminth driven gut inflammation and microbial translocation associate with altered vaccine responses in rural Uganda. NPJ vaccines, 10(1), 56.

Vargas-Montes M, et al. (2025) T-cell activation of Toxoplasma gondii positive donors by maltodextrin nanoparticles formulated with killed Toxoplasma gondii. BMC infectious diseases, 25(1), 279.

Yi D, et al. (2025) Chimeric hemagglutinin and M2 mRNA vaccine for broad influenza subtype protection. NPJ vaccines, 10(1), 113.

Zhang Y, et al. (2025) Integrating Single-Cell Biophysical and Transcriptomic Features to Resolve Functional Heterogeneity in Mantle Cell Lymphoma. bioRxiv : the preprint server for biology.

Saidoune F, et al. (2025) Enhanced TLR7-dependent production of type I interferon by pDCs underlies pandemic chilblains. The Journal of experimental medicine, 222(7).

Kawakita T, et al. (2025) ARNAX is an ideal adjuvant for COVID-19 vaccines to enhance antigen-specific CD4+ and CD8+ T-cell responses and neutralizing antibody induction. Journal of virology, 99(5), e0229024.

Osborn G, et al. (2025) Hyperinflammatory repolarisation of ovarian cancer patient macrophages by anti-tumour IgE antibody, MOv18, restricts an immunosuppressive macrophage:Treg cell interaction. Nature communications, 16(1), 2903.

de Oliveira B, et al. (2025) Characterization of a novel Leishmania antigen containing a repetitive domain and its potential use as a prophylactic and therapeutic vaccine. mSphere, 10(5), e0009725.

Jagne YJ, et al. (2025) Compartmentalised mucosal and blood immunity to SARS-CoV-2 is associated with high seroprevalence before the Delta wave in Africa. Communications medicine, 5(1), 178.

Beffinger M, et al. (2025) FcRn-silencing of IL-12Fc prevents toxicity of local IL-12 therapy and prolongs survival in experimental glioblastoma. Nature communications, 16(1), 4751.

Zhang F, et al. (2025) M cells targeted H. pylori antigen SAM-FAde displayed on bacterium-like particles induce protective immunity. Journal of nanobiotechnology, 23(1), 23.

Reddersen K, et al. (2025) Tattooed human in vitro skin model for testing the biocompatibility of tattoo inks and healing progression after tattooing. Scientific reports, 15(1), 2277.

Wang B, et al. (2025) Lyophilized monkeypox mRNA lipid nanoparticle vaccines with long-term stability and robust immune responses in mice. Human vaccines & immunotherapeutics, 21(1), 2477384.

Ji S, et al. (2025) Large-scale transcript variants dictate neoepitopes for cancer immunotherapy. *Science advances*, 11(5), eado5600.

Ansaryan S, et al. (2025) Multimodal Nanoplasmonic and Fluorescence Imaging for Simultaneous Monitoring of Single-Cell Secretory and Intracellular Dynamics. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 12(16), e2415808.

Xia M, et al. (2025) Baseline HBsAg quantitative and CD4 T cell counts are associated with HBsAg loss in people living with HIV/HBV coinfection after combined antiretroviral therapy. *Frontiers in cellular and infection microbiology*, 15, 1381826.

Ao D, et al. (2025) A promising mRNA vaccine derived from the JN.1 spike protein confers protective immunity against multiple emerged Omicron variants. *Molecular biomedicine*, 6(1), 13.

Wang S, et al. (2025) Structure-guided design of a prefusion GPC trimer induces neutralizing responses against LASV. *NPJ vaccines*, 10(1), 37.

Petro-Turnquist EM, et al. (2025) Epitope-optimized vaccine elicits enduring immunity against swine influenza A virus. *Nature communications*, 16(1), 4046.

Tran TBT, et al. (2025) In Vitro Expansion and Transduction of Primary NK Cells Using Feeder Cells Expressing Costimulatory Molecules and IL-21. *Cancer science*, 116(7), 1847.